ePT--the Electronic Newsletter of Pharmaceutical Technology
Geneva, Switzerland (Oct. 23)-Aiming to increase capacity for producing influenza pandemic vaccines, the World Health Organization has identified strategies and practical solutions for reducing the anticipated gap in the global vaccine supply.
Geneva, Switzerland (Oct. 23)-Aiming to increase capacity for producing influenza pandemic vaccines, the World Health Organization (www.who.int) has identified strategies and practical solutions for reducing the anticipated gap in the global vaccine supply. A result of the organization’s consultation with more than 120 scientists from national immunization programs, regulatory agencies, and vaccine manufacturers worldwide, The Global Pandemic Influenza Action Plan to Increase Vaccine Supply calls for immediate action details short-, mid-, and long-term approaches to expand “surge capacity” and boost production before and during a possible influenza pandemic.
The plan identifies three main approaches: an increase in seasonal vaccine use, an increase in production capacity, and an increase in research and development. According to the document, “Should there be a pandemic that appears to cause high mortality, there will probably be calls to vaccinate the global population-currently estimated to be 6.7 billion.” Current capacity is estimated at 350 million doses with 2008-2009 projections not exceeding 2.34 billion doses.
One short-term solution would be to provide surge capacity by leveraging antigen-sparing methods. Among the most promising strategies are increasing production yields, increasing the construction of production plants in both developing and industrialized countries, increasing the production of live attenuated influenza vaccines, and further development of adjuvanted vaccines with adjuvants widely used in licensed vaccines.
On Oct. 23, the US government pledged to support WHO’s influenza vaccine development and manufacturing infrastructure with a $10 million contribution.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.